HIV drugs are not big money makers and pharmaceutical companies do not spend much R&D dollars on them for that reason."Pfizer announced today that marketing authorization applications for Maraviroc will get accelerated review in  the United States and Europe. Accelerated reviews are given to those medicines that, if approved, would bring about noticeable improvements over current therapies.If approved by the regulatory agencies, Maraviroc will be the first in a new class of HIV/AIDS treatments called CCR5 antagonists that work by blocking viral entry."(www.pfizer.com)